P. Schöffski

488 total citations
14 papers, 396 citations indexed

About

P. Schöffski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, P. Schöffski has authored 14 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in P. Schöffski's work include Cancer Treatment and Pharmacology (5 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). P. Schöffski is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). P. Schöffski collaborates with scholars based in Germany, Belgium and Netherlands. P. Schöffski's co-authors include Hans‐Joachim Schmoll, Carsten Bokemeyer, A. Gerl, J. Beyer, J. Casper, A. Harstrick, Lothar Kanz, N. Niederle, Herlinde Dumez and Sandrine Marréaud and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical Oncology.

In The Last Decade

P. Schöffski

13 papers receiving 386 citations

Peers

P. Schöffski
Jennifer A. Grabowsky United States
Ryouichi Hamasuna Japan
Desamparados Roda Spain
Ignacio Wistuba United States
Nirupa Murugaesu United Kingdom
E Patsouris Greece
O. I. Olopade United States
Jamileh Hashemi Sweden
Ruud van der Noll Netherlands
Takumi Irie Japan
Jennifer A. Grabowsky United States
P. Schöffski
Citations per year, relative to P. Schöffski P. Schöffski (= 1×) peers Jennifer A. Grabowsky

Countries citing papers authored by P. Schöffski

Since Specialization
Citations

This map shows the geographic impact of P. Schöffski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Schöffski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Schöffski more than expected).

Fields of papers citing papers by P. Schöffski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Schöffski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Schöffski. The network helps show where P. Schöffski may publish in the future.

Co-authorship network of co-authors of P. Schöffski

This figure shows the co-authorship network connecting the top 25 collaborators of P. Schöffski. A scholar is included among the top collaborators of P. Schöffski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Schöffski. P. Schöffski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
Doussau, A., Rodolphe Thiébaut, Birgit Geoerger, et al.. (2014). A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials. Annals of Oncology. 26(2). 422–428. 9 indexed citations
4.
5.
Poorten, Vincent Vander, Sandra Nuyts, Esther Hauben, et al.. (2011). Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer.. PubMed. 7(1). 1–6. 29 indexed citations
6.
Schöffski, P., Ahmad Awada, Herlinde Dumez, et al.. (2010). Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3061–3061. 6 indexed citations
7.
Schöffski, P., Herlinde Dumez, Nicoletta Brega, et al.. (2008). Phase I safety and pharmacokinetic (PK) study of SU014813 (S) in combination with docetaxel (D) in patients (pts) with solid tumors (STs). Journal of Clinical Oncology. 26(15_suppl). 3554–3554. 1 indexed citations
8.
Jones, Suzanne F., Howard A. Burris, Herlinde Dumez, et al.. (2008). Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results. Journal of Clinical Oncology. 26(15_suppl). 2517–2517. 16 indexed citations
9.
10.
Martinelli, Elisa Martina, Chris H. Takimoto, A.T. van Oosterom, et al.. (2005). AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: Preliminary phase 1 results. Journal of Clinical Oncology. 23(16_suppl). 3039–3039. 28 indexed citations
11.
Schöffski, P., P. Fumoleau, Mario Campone, et al.. (2004). Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Annals of Oncology. 15(12). 1816–1824. 72 indexed citations
12.
Bokemeyer, Carsten, A. Gerl, P. Schöffski, et al.. (1999). Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer. Journal of Clinical Oncology. 17(2). 512–512. 104 indexed citations
13.
Köhne, C.-H., et al.. (1996). The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.. PubMed. 6(4). 206–10. 1 indexed citations
14.
Schmoll, Hans‐Joachim, W. Hiddemann, H. Knipp, et al.. (1992). Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.. PubMed. 19(2 Suppl 3). 191–6. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer A. Grabowsky Breakdown of academic impact, for papers by Ryouichi Hamasuna Breakdown of academic impact, for papers by Desamparados Roda Breakdown of academic impact, for papers by Ignacio Wistuba Breakdown of academic impact, for papers by Nirupa Murugaesu Breakdown of academic impact, for papers by E Patsouris Breakdown of academic impact, for papers by O. I. Olopade Breakdown of academic impact, for papers by Jamileh Hashemi Breakdown of academic impact, for papers by Ruud van der Noll Breakdown of academic impact, for papers by Takumi Irie
Rankless by CCL
2026